August 26, 2022
Life Sciences
  • Pfizer Inc. said its vaccine to protect older adults against the respiratory syncytial virus (RSV) effectively reduced severe cases of the illness by nearly 86 percent. The drugmaker, which views the RSVpreF vaccine as a critical offering in its lineup of experimental medicines, also said the shot lowered the risk of milder RSV cases in adults 60 and older by almost 67 percent. (Articles here and here)